Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
- PMID: 26811150
- PMCID: PMC4973858
- DOI: 10.7326/M15-0983
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
Abstract
Background: The fecal immunochemical test (FIT) is a common method for colorectal cancer (CRC) screening, yet its acceptability and performance over several rounds of annual testing are largely unknown.
Objective: To assess FIT performance characteristics over 4 rounds of annual screening.
Design: Retrospective cohort study.
Setting: Kaiser Permanente Northern and Southern California.
Patients: 323 349 health plan members aged 50 to 70 years on their FIT mailing date in 2007 or 2008 who completed the first round of FIT and were followed for up to 4 screening rounds.
Measurements: Screening participation, FIT positivity (≥20 µg of hemoglobin/g), positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
Results: Of the patients invited for screening, 48.2% participated in round 1. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of round 1 participants crossed over to endoscopy over 4 screening rounds-7.0% due to a positive FIT result. The FIT positivity rate (5.0%) and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in round 1. Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within 1 year of testing, including 84.5% in round 1 and 73.4% to 78.0% in subsequent rounds.
Limitation: Screening detection, rather than long-term cancer prevention, was evaluated.
Conclusion: Annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening.
Primary funding source: National Institutes of Health.
Conflict of interest statement
Figures
Similar articles
-
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
-
Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3. Gut. 2018. PMID: 29101260
-
Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010. Health Technol Assess. 2019. PMID: 30618357 Free PMC article. Clinical Trial.
-
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
-
[Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Gastroenterol Hepatol. 2009. PMID: 19577340 Review. Spanish.
Cited by
-
Screening and Surveillance of Colorectal Cancer: A Review of the Literature.Cancers (Basel). 2024 Aug 1;16(15):2746. doi: 10.3390/cancers16152746. Cancers (Basel). 2024. PMID: 39123473 Free PMC article. Review.
-
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.JAMA Netw Open. 2024 Jul 1;7(7):e2423671. doi: 10.1001/jamanetworkopen.2024.23671. JAMA Netw Open. 2024. PMID: 39028667 Free PMC article.
-
Strategic use of resources to enhance colorectal cancer screening for patients with diabetes (SURE: CRC4D) in federally qualified health centers: a protocol for hybrid type ii effectiveness-implementation trial.BMC Prim Care. 2024 Jul 5;25(1):242. doi: 10.1186/s12875-024-02496-0. BMC Prim Care. 2024. PMID: 38969987 Free PMC article.
-
Patterns of Care Following a Positive Fecal Blood Test for Colorectal Cancer: A Mixed Methods Study.J Gen Intern Med. 2024 May 21. doi: 10.1007/s11606-024-08764-0. Online ahead of print. J Gen Intern Med. 2024. PMID: 38771535
-
Colorectal Cancer: Epidemiology, Risk Factors, and Prevention.Cancers (Basel). 2024 Apr 17;16(8):1530. doi: 10.3390/cancers16081530. Cancers (Basel). 2024. PMID: 38672612 Free PMC article. Review.
References
-
- Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73. doi: 10.1002/cncr.24760. - DOI - PMC - PubMed
-
- U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–37. - PubMed
-
- Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. American Cancer Society Colorectal Cancer Advisory Group Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–95. doi: 10.1053/j.gastro.2008.02.002. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical